Please login to the form below
Spectrum appoints Dr Dalna Harvey as regulatory project manager
She brings experience gained at firms such as Parexel, Chiron and Wyeth
Spectrum Regulatory Solutions has appointed Dr Dalna Harvey as regulatory project manager
She brings to the Horsham, UK-based healthcare consultancy a wealth of experience in regulatory affairs, gained from working for companies such as Parexel, Chiron Corporation, Wyeth Pharmaceuticals, Pliva London and, most recently, Woodley BioReg.
Dr Angela Gisby, managing director of Spectrum, said: “We are pleased to welcome Dalna to Spectrum and we look forward to the expert contribution she will bring to the business, particularly in the area of regulatory intelligence.”
In her new role Dr Harvey will will be responsible for updating Spectrum's global healthcare clients on legislation amendments, providing strategic and technical advice and maintaining marketing authorisations.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Avalere Health
Avalere Health is a leading global commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Working from advisory to...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
